Abstract
Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have